Disease-modifying activity of SB 273005, an orally active, nonpeptide αvβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

Arthritis and Rheumatism

Volumn 44, Issue 1, 2001, Pages 128-137

  Badger, Alison M ^a   Blake, Simon ^a   Kapadia, Rasesh ^a   Sarkar, Susanta ^a   Levin, Joshua ^a   Swift, Barbara A ^a   Hoffman, Sandy J ^a   Stroup, George B ^a   Miller, William H ^a   Gowen, Maxine ^a   Lark, Michael W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SB 273005; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ABSORPTIOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DENSITY; BONE MINERAL; DISEASE ACTIVITY; HISTOPATHOLOGY; INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPHYLAXIS; RAT;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; BONE DENSITY; CARTILAGE, ARTICULAR; EDEMA; MAGNETIC RESONANCE IMAGING; MALE; PYRIDINES; RATS; RATS, INBRED LEW; RECEPTORS, VITRONECTIN;

EID: 0035150588     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO;2-M     Document Type: Article

References (28)

1. 3 for angiogenesis
2. 3 integrin "vitronectin receptor"
3. v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
4. Integrin distribution in malignant melanoma: Association of β3 subunit with tumor progression
5. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
6. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy
7. v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitots
8. 3 blocks human breast cancer growth and angiogenesis in human skin
9. Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture
10. Integrins on rat osteoclasts and characterization of two monoclonal antibodies (F4 and F11) to rat beta 3
11. Biochemical characterization of human osteoclast integrins: Osteoclasts express alpha v beta 3, alpha 2 beta 1, alpha v beta 1 integrins
12. Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ
13. 3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat
14. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD) - Containing protein
15. Direct demonstration of inhibitory effect of echistatin on PTH-induced bone resorption in vivo in mice
16. The integrin ligand echistatin prevents bone loss in ovariectomized mice rats
17. 5 is expressed on avian osteoclast precursors and regulated by retinoic acid
18. 3 integrin inhibits bone resorption in vitro prevents osteoporosis in vivo
19. Design characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
20. Antagonism of the osteoclast vitronectin receptor with an orally active non-peptide inhibitor prevents cancellous bone loss in the ovariectomized rat
21. Highly orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
22. Discovery of orally active non-peptide vitronectin receptor antagonists based on a 2-benzazapine gly-asp mimetic
23. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis
24. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: Reduction of vascular endothelial growth factor (VEGF)
25. 3 antagonist
26. Microprocessor-assisted plethysmograph for the measurement of mouse paw volume
27. 3 integrin involved in adhesion of leukocytes to endothelium
28. An anti-platelet-endothelial molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane